StockNews.com initiated coverage on shares of Pulmatrix (NASDAQ:PULM – Free Report) in a research report report published on Sunday. The firm issued a hold rating on the biotechnology company’s stock.
Pulmatrix Stock Performance
Pulmatrix stock opened at $2.05 on Friday. Pulmatrix has a fifty-two week low of $1.55 and a fifty-two week high of $2.75. The firm’s 50-day simple moving average is $2.07 and its 200 day simple moving average is $2.03. The stock has a market cap of $7.48 million, a PE ratio of -0.78 and a beta of 0.99.
Pulmatrix (NASDAQ:PULM – Get Free Report) last posted its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.87) EPS for the quarter. The firm had revenue of $1.55 million for the quarter. Pulmatrix had a negative return on equity of 46.86% and a negative net margin of 95.18%.
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Read More
- Five stocks we like better than Pulmatrix
- Comparing and Trading High PE Ratio Stocks
- Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025
- Upcoming IPO Stock Lockup Period, Explained
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- What Are Growth Stocks and Investing in Them
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
